Pfizer

Syndicate content

India considers price controls for patented drugs

drugs4_0.jpg.crop_display.jpg

India is planning to rein in prices of expensive patented drugs to make medicines affordable to its predominantly poor population, a top government official said on Friday.

Govt defers decision on M&M, Pfizer FDI applications

pfizer.jpg.crop_display.jpg

Government has deferred decision on Mahindra group's proposal to bring in FDI for a defence production joint venture and on another application by pharma major Pfizer to bring in foreign equity in a c

Biocon, Pfizer call off $350 mn pact on insulin products

Pfizer_Finland_HQ_February_.jpg.crop_display.jpg

Biocon and US drug major Pfizer on Tuesday called off USD 350 million global alliance to commercialise the Bangalore-based firm's biosimilar versions of insulin and insulin analog products.

"The comp

Biocon Q2 net drops as energy costs, wages rise

kiranmazumdar-dc.jpg.crop_display.jpg

Biocon Ltd, India top biotechnology company, reported a 4 per cent drop in quarterly profit due to higher energy costs and rise in wages, but said strong demand from branded formulations offered oppor

DRL may contest Pfizer patent suit

Jan. 5: Dr Reddy’s Laboratories (DRL) is likely to contest a patent infringement case filed against it by global pharma giant Pfizer over its cholesterol lowering drug atorvastatin.

Dr Reddy’s had fi

No Articles Found

No Articles Found

No Articles Found

I want to begin with a little story that was told to me by a leading executive at Aptech. He was exercising in a gym with a lot of younger people.

Shekhar Kapur’s Bandit Queen didn’t make the cut. Neither did Shaji Karun’s Piravi, which bagged 31 international awards.